Can Seaport’s GlyphAgo overcome agomelatine’s liver problem? New Phase 1 data sharpen the test
Seaport's GlyphAgo shows 6.8-fold higher bioavailability as anxiety trials advance, but its potential to reduce liver risks remains unproven.
Pharma & Biotech
Pharma & Biotech
GlyphAgo boosted drug bioavailability 6.8-fold. Can Seaport solve agomelatine’s liver safety challenge?
Seaport's GlyphAgo improved agomelatine exposure in Phase 1. New Phase 2 trials will test efficacy, liver safety and anxiety outcomes.